Macitentan for treatment of CTEPH: why MERIT merits attention
Author:
- 1 October 2017
- journal article
- retracted article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 5 (10) , 762-763
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled studyThe Lancet Respiratory Medicine, 2017
- The pathophysiology of chronic thromboembolic pulmonary hypertensionEuropean Respiratory Review, 2017
- Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary HypertensionCirculation, 2016
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculatureEuropean Respiratory Journal, 2014
- Riociguat for the Treatment of Chronic Thromboembolic Pulmonary HypertensionNew England Journal of Medicine, 2013
- Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertensionThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary HypertensionJACC, 2008
- Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary HypertensionChest, 2008
- Prostacyclin Therapy Before Pulmonary Thromboendarterectomy in Patients With Chronic Thromboembolic Pulmonary Hypertension*Chest, 2003